Background:
The emergence of the Omicron BA.5 sublineage in February 2022 raised concerns due to its ability to escape neutralizing antibodies induced by ancestral spike mRNA vaccines and natural infection with prior SARS-CoV-2 variants. Bivalent COVID-19 vaccines, containing mRNA for both ancestral and Omicron BA.5 spike proteins, were developed to enhance immune responses against the BA.5 sublineage. However, studies have shown that these bivalent vaccines do not induce stronger T cell responses to the BA.5 spike protein than monovalent vaccines containing only ancestral spike mRNA. We tested the hypothesis that this was due to the preferential expansion of cross-reactive memory T cells rather than naive BA.5 mono-reactive T cells.
Methods:
We used the ELISpot assay to determine the targeted epitopes and the functional expansion of specific T Cells (FEST) assay to assess the percentage of CD4+ T cells that cross-recognized both ancestral and BA.5 spike proteins compared to those that were mono-reactive for each protein. We conducted this analysis in two distinct cohorts: 20 healthy donors (HDs) and 20 people living with HIV (PLWH) on suppressive antiretroviral therapy. All the participants received either the Pfizer-BioNTech (BNT162b2) or Moderna (mRNA-1273) SARS-CoV-2 ancestral spike/BA.5 spike bivalent vaccine.
Results:
We found robust T cell responses to both ancestral and BA.5 spike proteins in both HDs and PLWH. Importantly, the FEST assay revealed that a predominant percentage of these responses were cross-reactive CD4+ T cells. Specifically, only 8.9% and 3.8% of spike-specific CD4+ T cell receptors were mono-reactive to BA.5 spike protein in HDs and PLWH respectively. Additionally, we conducted an in-depth analysis of the individual ancestral spike protein epitopes targeted by T cells in bivalent vaccine recipients. We found that more than 80% of these epitopes were ones that did not contain BA.5 mutations.
Conclusions:
In conclusion, our study suggests that the current bivalent vaccines do not effectively induce substantial BA.5-mono-reactive T cell responses; instead, cross-reactive T cells dominate the spike-specific T cell response. These findings have significant implications for future COVID vaccine strategies.